STOCK TITAN

Firefly Neuroscience (NASDAQ: AIFF) slashes authorized shares to 101M

(Moderate)
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Firefly Neuroscience, Inc. held its 2026 annual meeting on August 5, 2026, where stockholders approved Amendment No. 2 to the 2024 Long-Term Incentive Plan, increasing the Plan Share Limit by 2,000,000 shares of common stock and updating the plan’s evergreen provision. Stockholders also elected Arun Menawat as a Class III director to serve until 2029 and approved, on a non-binding advisory basis, compensation for named executive officers.

Stockholders approved a charter amendment decreasing total authorized capital from 5,001,000,000 shares to 101,000,000, consisting of 100,000,000 shares of common stock and 1,000,000 shares of preferred stock, effective August 5, 2026. They ratified CBIZ Canada, LLP as independent auditor and approved an adjournment proposal. Shares outstanding on the June 8, 2026 record date were 15,604,571, with 9,703,536 shares represented, constituting a quorum.

Positive

  • Stockholders approved a major reduction in authorized share capital from 5,001,000,000 to 101,000,000 shares, materially tightening the company’s capacity for future equity issuance.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Authorized shares before amendment 5,001,000,000 shares Total authorized capital prior to Certificate of Amendment No. 2
Authorized shares after amendment 101,000,000 shares Total authorized capital after Charter Amendment Authorization
Authorized common stock 100,000,000 shares Common stock authorized under amended certificate of incorporation
Authorized preferred stock 1,000,000 shares Preferred stock authorized under amended certificate of incorporation
LTIP share increase 2,000,000 shares Increase to maximum number of shares available under 2024 Long-Term Incentive Plan
Shares outstanding at record date 15,604,571 shares Common stock issued, outstanding and entitled to vote as of June 8, 2026
Shares represented at meeting 9,703,536 shares Shares present in person or by proxy, constituting a quorum at the annual meeting
Auditor ratification votes for 9,500,723 votes Votes in favor of ratifying CBIZ Canada, LLP as independent auditor for 2026
Long-Term Incentive Plan financial
"approved Amendment No. 2 to the Firefly Neuroscience, Inc. 2024 Long-Term Incentive Plan"
A long-term incentive plan is a company program that pays executives or employees with stock, options, or cash tied to multi-year performance goals, where the rewards become theirs only after meeting conditions over time. Think of it as a delayed bonus or retirement-style reward that aligns employees’ interests with shareholders by encouraging them to boost long-term value; investors watch these plans because they affect pay costs, share dilution and management incentives.
evergreen provision financial
"increase the Plan Share Limit by 2,000,000 shares of common stock, and updated the Plan’s evergreen provision"
An evergreen provision is a clause in a financing or contract that automatically renews or replenishes the arrangement unless one party actively cancels it, like a subscription that keeps renewing each term. For investors it matters because it creates predictable, ongoing access to funding or ongoing contractual obligations — helping liquidity and planning — but can also hide long-term commitments or dilution risks if not reviewed.
Amended and Restated Certificate of Incorporation regulatory
"Amendment No. 2 of Amended and Restated Certificate of Incorporation, As Amended"
A company’s amended and restated certificate of incorporation is an updated version of its foundational legal charter that replaces the older document and folds in all changes into one clear copy; it spells out corporate structure, classes of stock, shareholder rights and key governance rules. Investors care because it can change who controls the company, how votes are counted, what claims shareholders have on assets or dividends, and can introduce or remove protections against takeovers—like updating a house title after a major renovation to show who owns what and under what rules.
broker non-votes financial
"Arun Menawat ... 4,324,584 For ... 106,395 Withheld ... 5,272,557 Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
non-binding, advisory basis financial
"a proposal to approve, on a non-binding, advisory basis, the compensation paid to our named executive officers"
A non-binding, advisory basis means a recommendation or decision that carries no legal force and does not obligate the parties to act; it’s similar to a friendly suggestion rather than a signed promise. For investors, this matters because such guidance can influence market expectations and management plans but offers no guarantee of follow-through, so investors should treat it as informative input rather than a firm commitment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What key items did Firefly Neuroscience (AIFF) stockholders approve at the 2026 annual meeting?

Stockholders approved six proposals, including electing Arun Menawat as a Class III director, ratifying CBIZ Canada, LLP as auditor, approving executive pay on a non-binding basis, expanding the 2024 Long-Term Incentive Plan by 2,000,000 shares, and reducing total authorized shares to 101,000,000.

How did Firefly Neuroscience (AIFF) change its authorized share capital?

Stockholders approved a charter amendment decreasing total authorized shares from 5,001,000,000 to 101,000,000, made up of 100,000,000 common and 1,000,000 preferred shares. The Certificate of Amendment became effective on August 5, 2026, after filing with the Delaware Secretary of State.

What changes were made to the Firefly Neuroscience (AIFF) 2024 Long-Term Incentive Plan?

Stockholders approved Amendment No. 2 to the 2024 Long-Term Incentive Plan, increasing the Plan Share Limit by 2,000,000 shares of common stock and updating the plan’s evergreen provision. These changes expand the equity available for future grants to eligible participants under the plan.

What was the quorum and voting base for Firefly Neuroscience (AIFF) at the 2026 annual meeting?

As of the June 8, 2026 record date, there were 15,604,571 shares of common stock outstanding and entitled to vote. A total of 9,703,536 shares were present in person or represented by proxy at the meeting, which constituted a quorum.

Who was elected to the Firefly Neuroscience (AIFF) board at the 2026 annual meeting?

Stockholders elected Arun Menawat as the Class III director to the Board of Directors. He will serve until the 2029 annual meeting of stockholders, or until his successor has been duly elected and qualified, according to the approved proposal language.

Which auditor did Firefly Neuroscience (AIFF) stockholders ratify for fiscal year 2026?

Stockholders ratified CBIZ Canada, LLP (formerly Marcum Canada, LLP) as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 9,500,723 votes for, 21,341 votes against, and 181,472 abstentions recorded on the proposal.
false --12-31 0000803578 0000803578 2026-08-05 2026-08-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 5, 2026

 

FIREFLY NEUROSCIENCE, INC.
(Exact name of registrant as specified in its charter)

 

Delaware   001-41092   54-1167364
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

1100 Military Road, Kenmore, NY   14217
(Address of principal executive offices)   (Zip Code)

 

(888) 237-6412
(Registrant’s telephone number, including area code)

 

 
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   AIFF   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

 

Emerging Growth Company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On August 5, 2026, at the 2026 annual meeting of stockholders (the “Annual Meeting”) of Firefly Neuroscience, Inc., a Delaware corporation (the “Company”), the Company’s stockholders approved Amendment No. 2 to the Firefly Neuroscience, Inc. 2024 Long-Term Incentive Plan (the “Plan Amendment”), which amended the Firefly Neuroscience, Inc. 2024 Long-Term Incentive Plan (as amended, the “Plan”). The approval of the Plan Amendment increased the maximum number of shares available for grant under the Plan (the “Plan Share Limit”) by 2,000,000 shares of common stock, par value $0.0001 per share (the “Common Stock”), and updated the Plan’s evergreen provision. A description of the Plan is set forth in the Company’s Definitive Proxy Statement  on Schedule 14A, as filed with the Securities and Exchange Commission (the “SEC”) on July 9, 2026 (the “Proxy Statement”), the relevant portions of which are incorporated by reference herein.

 

A copy of the Plan Amendment is filed as Exhibit 10.1 to this Current Report on Form 8-K, and the description above is qualified in its entirety by reference to the full text of such exhibit.

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

Amendment No. 2 of Amended and Restated Certificate of Incorporation, As Amended

 

In connection with the approval by the stockholders of the Company at the Annual Meeting of a proposal to amend the Amended and Restated Certificate of Incorporation of the Company, as amended, to decrease the total number of authorized shares from 5,001,000,000 to 101,000,000, consisting of (i) 100,000,000 shares of Common Stock, and (ii) 1,000,000 shares of preferred stock, par value $0.0001 per share (the “Preferred Stock”) (the “Charter Amendment Authorization”), on August 5, 2026, the Company filed the Amendment No. 2 of Amended and Restated Certificate of Incorporation, As Amended (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware, which became effective on August 5, 2026, to effect the Charter Amendment Authorization.

 

The foregoing description of the Certificate of Amendment is a summary only and is qualified in its entirety by reference to the complete text of the Certificate of Amendment, a copy of which is attached as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated by reference herein. Additional information regarding the submission and approval of the proposal relating to the Charter Amendment Authorization is disclosed under Item 5.07 below.

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On August 5, 2026, the Company held the Annual Meeting. As of June 8, 2026, the record date for the Annual Meeting, there were 15,604,571 shares of common stock, issued and outstanding and entitled to vote on the proposals presented at the Annual Meeting, of which 9,703,536 shares were present in person or represented by proxy, which constituted a quorum. The holders of shares of the common stock are entitled to one vote for each share held.

 

At the Annual Meeting, the stockholders voted on six proposals, each of which is described in greater detail in the Proxy Statement, the relevant portions of which are incorporated by reference herein. At the Annual Meeting, stockholders approved Proposals 1, 2, 3, 4, 5 and 6, each of which was presented for a vote. Set forth below are the final voting results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting.

 

Proposal 1: A proposal to elect Arun Menawat as the Class III director to the Board of Directors (the “Board”) to serve until the annual meeting of stockholders to be held in 2029, or until his successor has been duly elected and qualified. The proposal was approved as set forth below:

 

Nominee  For   Withheld   Broker
Non-Votes
 
Arun Menawat   4,324,584    106,395    5,272,557 

 

Proposal 2: A proposal to ratify the appointment of CBIZ Canada, LLP (formerly known as Marcum Canada, LLP) as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026. The proposal was approved as set forth below:

 

For   Against     Abstain  
9,500,723     21,341       181,472  

 

1

 

Proposal 3: A proposal to approve, on a non-binding, advisory basis, the compensation paid to our named executive officers. The proposal was approved as set forth below:

 

For   Against     Abstain     Broker Non-Votes  
4,331,361     76,601       23,017       5,272,557  

 

Proposal 4: A proposal to approve Amendment No. 2 to the Firefly Neuroscience, Inc. 2024 Long-Term Incentive Plan, as amended, to increase the maximum number of shares available for grant under the Plan by 2,000,000 shares of common stock and update the Plan’s evergreen provision. The proposal was approved as set forth below:

 

For   Against     Abstain     Broker Non-Votes  
4,047,217     361,601       22,161       5,272,557  

 

Proposal 5: A proposal to approve Certificate of Amendment No. 2 of Amended and Restated Certificate of Incorporation of Firefly Neuroscience, Inc., as amended, to decrease the total number of authorized shares from 5,001,000,000 to 101,000,000, consisting of (i) 100,000,000 shares of Common Stock, and (ii) 1,000,000 shares of Preferred Stock. The proposal was approved as set forth below:

 

For   Against     Abstain  
9,222,775     268,441       212,320  

 

Proposal 6: A proposal to approve the adjournment of the Annual Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of any one or more of the foregoing proposals. The proposal was approved as set forth below:

 

For   Against     Abstain  
9,117,363     387,451       198,722  

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description of Exhibit
3.1   Amendment No. 2 of Amended and Restated Certificate of Incorporation of Firefly Neuroscience, Inc., As Amended
10.1   Amendment No. 2 to the Firefly Neuroscience, Inc. 2024 Long-Term Incentive Plan
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 7, 2026 FIREFLY NEUROSCIENCE, INC.
   
  /s/ Greg Lipschitz
  Name:  Greg Lipschitz
  Title: Chief Executive Officer

 

3

 

Filing Exhibits & Attachments

5 documents